Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies - real-world data from the IG TATRY study.
Edyta Heropolitanska-PliszkaMałgorzata PacBarbara PietruchaEdyta MachuraAnna Pukas-BochenekEwelina ChrobakEwa BienMagdalena MalanowskaAnna Pituch-NoworolskaSzymon DrygałaMarta KamieniakJakub KasprzakMonika Mach-TomalskaPublished in: Expert review of clinical immunology (2023)
The trial is registered at ClinicalTrials.gov (NCT04636502).